Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Raph L Hamers

Showing results (1-10 of 144) with videos related to

Pageof 15
Sort By:
The Lancet. HIV|February 6, 2016
Enhancement of clinical decision making in HIV care in AfricaRaph L Hamers
The Lancet. Infectious Diseases|February 9, 2019
Dolutegravir for second-line antiretroviral therapyRaph L Hamers
The Lancet. HIV|September 24, 2016
Next-generation sequencing and HIV drug resistance surveillanceRaph L Hamers, Roger Paredes
The Lancet. HIV|December 4, 2018
Dolutegravir in sub-Saharan Africa: context is crucialJienchi Dorward, Raph L Hamers
The Lancet. Microbe|May 11, 2022
Pan-resistant HIV-1: what's next?Raph L Hamers, Seth C Inzaule
The Lancet. Global Health|June 16, 2018
Antibiotic consumption in low-income and middle-income countriesRaph L Hamers, H Rogier van Doorn
The Lancet. HIV|May 11, 2020
Is increasing pretreatment HIV drug resistance a real menace or minor detail?Seth C Inzaule, Raph L Hamers, Silvia Bertagnolio
The New England Journal of Medicine|January 14, 2016
Benznidazole for Chronic Chagas' CardiomyopathyRaph L Hamers, Tom van Gool, Abraham Goorhuis
The Lancet. Infectious Diseases|October 31, 2021
Transaminases and serum albumin as early predictors of severe dengueGilbert Lazarus, Erni J Nelwan, Raph L Hamers
The Lancet. HIV|June 3, 2026
HIV prevention must incorporate acute HIV infection screeningRaph L Hamers, Pande Putu Januraga, Eduard J Sanders
Pageof 15

Showing results (1-10 of 144) with videos related to

Sort By:
Pageof 15
The Lancet. HIV|February 6, 2016
Enhancement of clinical decision making in HIV care in AfricaRaph L Hamers
The Lancet. Infectious Diseases|February 9, 2019
Dolutegravir for second-line antiretroviral therapyRaph L Hamers
The Lancet. HIV|September 24, 2016
Next-generation sequencing and HIV drug resistance surveillanceRaph L Hamers, Roger Paredes
The Lancet. HIV|December 4, 2018
Dolutegravir in sub-Saharan Africa: context is crucialJienchi Dorward, Raph L Hamers
The Lancet. Microbe|May 11, 2022
Pan-resistant HIV-1: what's next?Raph L Hamers, Seth C Inzaule
The Lancet. Global Health|June 16, 2018
Antibiotic consumption in low-income and middle-income countriesRaph L Hamers, H Rogier van Doorn
The Lancet. HIV|May 11, 2020
Is increasing pretreatment HIV drug resistance a real menace or minor detail?Seth C Inzaule, Raph L Hamers, Silvia Bertagnolio
The New England Journal of Medicine|January 14, 2016
Benznidazole for Chronic Chagas' CardiomyopathyRaph L Hamers, Tom van Gool, Abraham Goorhuis
The Lancet. Infectious Diseases|October 31, 2021
Transaminases and serum albumin as early predictors of severe dengueGilbert Lazarus, Erni J Nelwan, Raph L Hamers
The Lancet. HIV|June 3, 2026
HIV prevention must incorporate acute HIV infection screeningRaph L Hamers, Pande Putu Januraga, Eduard J Sanders
Pageof 15